Your browser doesn't support javascript.
loading
Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia.
Lasalvia, Pieralessandro; Gil-Rojas, Yaneth; García, Ángel.
Affiliation
  • Lasalvia P; Department of Economic Studies, NeuroEconomix, Bogota, Colombia.
  • Gil-Rojas Y; Department of Economic Studies, NeuroEconomix, Bogota, Colombia.
  • García Á; Cardiology Unit, San Ignacio University Hospital. Pontificia Universidad Javeriana, Bogotá, Colombia.
Expert Rev Pharmacoecon Outcomes Res ; 22(6): 955-964, 2022 Sep.
Article in En | MEDLINE | ID: mdl-35259045
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Metformin Type of study: Health_economic_evaluation Aspects: Patient_preference Limits: Humans Country/Region as subject: America do sul / Colombia Language: En Journal: Expert Rev Pharmacoecon Outcomes Res Journal subject: FARMACOLOGIA Year: 2022 Document type: Article Affiliation country: Colombia Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Dipeptidyl-Peptidase IV Inhibitors / Metformin Type of study: Health_economic_evaluation Aspects: Patient_preference Limits: Humans Country/Region as subject: America do sul / Colombia Language: En Journal: Expert Rev Pharmacoecon Outcomes Res Journal subject: FARMACOLOGIA Year: 2022 Document type: Article Affiliation country: Colombia Country of publication: United kingdom